Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating activities:
Net income (loss)	$ (22,029,000)	$ (22,735,000)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, Depletion and Amortization	3,068,000	3,420,000
Amortization of Financing Costs and Discounts	373,000	1,712,000
Share-based compensation	8,170,000	6,347,000
Provision for doubtful accounts	(559,000)	2,596,000
Changes in operating assets and liabilities:
Accounts and unbilled receivables	(3,610,000)	8,889,000
Increase (Decrease) in Deferred Costs	867,000	763,000
Prepaid expenses and other assets	(395,000)	(701,000)
Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net	(173,000)	868,000
Accounts payable	2,012,000	579,000
Accrued liabilities	3,918,000	(3,840,000)
Accrued payroll and other employee benefits	(7,573,000)	(20,055,000)
Deferred revenue	11,502,000	(2,016,000)
Net cash provided by (used in) operating activities	(4,429,000)	(24,173,000)
Investing activities:
Purchases of property and equipment	(1,300,000)	(10,993,000)
Internal-use software development costs capitalized	0	(412,000)
Payments to Acquire Other Investments	(501,000)	0
Net cash provided by (used in) investing activities	(1,801,000)	(11,405,000)
Financing activities:
Proceeds from Stock Plans	1,596,000	1,364,000
Tax withholding related to net share settlement of restricted stock units	(352,000)	(20,172,000)
Net cash provided by (used in) financing activities	1,244,000	(18,808,000)
Effect of Exchange Rate on Cash and Cash Equivalents	(219,000)	91,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(5,205,000)	(54,295,000)
Cash and cash equivalents:
Beginning of period	329,134,000	306,077,000
End of period	323,929,000	251,782,000
Capital Expenditures Incurred but Not yet Paid	$ 328,000	$ 3,253,000